Drugs / Salmonella-IL2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04589234 | Oct 2020 → Dec 2030 expected | malignant pancreatic neoplasm | Salspera LLC | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salmonella-IL2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04589234 ↗ |
| Known as | Saltikva | “The study agent is Saltikva, an attenuated Salmonella Typhimurium containing the gene for human IL-2 (Salmonella-IL2).” NCT04589234 ↗ |
| Modality | Other / unclassified | “A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer.” PMID 41591505 ↗ Jan 2026 |
| Route | Oral | “multiple dose oral administration of Saltikva” NCT04589234 ↗ |